FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380079400> ?p ?o ?g. }

• W4380079400 endingPage "441" @default.
• W4380079400 startingPage "439" @default.
• W4380079400 abstract "Background: The Phase II L-MIND study led to accelerated US approval and EU conditional authorization of the CD19-targeted immunotherapy, tafasitamab, + lenalidomide (LEN) followed by tafasitamab monotherapy for patients (pts) with R/R DLBCL ineligible for autologous stem cell transplant (ASCT). Long-term L-MIND data further support the regimen. Here we present exploratory analyses of final 5-year (yr) efficacy in subgroups of interest. Methods: Pts (≥18 years) with ASCT-ineligible R/R DLBCL, 1–3 prior systemic therapies (incl. ≥1 targeting CD20) and ECOG PS 0–2 received tafasitamab for ≤12 28-day cycles (+ LEN), then alone until disease progression. Primary endpoint was objective response rate (ORR). Secondary endpoints included duration of response (DoR), progression-free survival (PFS) and overall survival (OS). Exploratory subgroup analyses including by International Prognostic Index (IPI) and time to progression after 1L (in pts with only 1 prior line) used Kaplan-Meier estimates of 5-yr endpoints. Results: As of 14 November 2022 in the full analysis set (FAS; n = 80), ORR was 57.5% [95% CI: 45.9–68.5]. Median treatment duration was 9.0 months (mo) [0.5–73.6] and median follow-up (mFU) for OS was 65.6 mo [59.9–70.3]). Median DoR was not reached (mFU: 44.0. mo [29.9–57.0]). Of 18 patients in follow-up for ≥5 years, 9 received tafasitamab until end of study per protocol, 9 discontinued while in remission. RR and 5-yr rates for DoR, PFS and OS showed long-term clinical activity in all pt subgroups (Table). Conclusion: In this 5-yr subgroup analysis, a long-term clinical benefit with tafasitamab + LEN followed by tafasitamab monotherapy was observed in all subgroups of clinical interest, including pts with poor prognosis risk factors. These data suggest this immunotherapy may have curative potential, which is being explored in further studies. Encore Abstract - previously submitted to ASCO 2023 The research was funded by: MorphoSys AG Keyword: Aggressive B-cell non-Hodgkin lymphoma Conflicts of interests pertinent to the abstract. J. Duell Research funding: MorphoSys AG, Regeneron P. Abrisqueta Consultant or advisory role: Janssen, Celgene, AbbVie, AstraZeneca Honoraria: Janssen, Celgene, AbbVie, AstraZeneca, Gilead Other remuneration: Speakers’ bureau: Janssen, Celgene, AbbVie, AstraZeneca, Gilead M. Dreyling Consultant or advisory role: AstraZeneca, BeiGene, BMS/Celgene, Gilead/Kite, Janssen, Lilly/Loxo, Novartis, Roche Research funding: AbbVie, Bayer, Celgene, Gilead/Kite, Janssen, Roche Other remuneration: Speakers' honoraria: AstraZeneca, BeiGene, Gilead/Kite, Janssen, Lilly, Novartis, Roche G. Gaidano Consultant or advisory role: AbbVie, AstraZeneca, BeiGene, Incyte, Janssen, Roche Other remuneration: Speaker’s Bureau: AbbVie, Janssen E. G. Barca Consultant or advisory role: Janssen, AbbVie, Gilead, Kiowa, EUSAPharma, Incyte, Lilly, BeiGene Educational grants: Janssen, AbbVie, EUSAPharma Other remuneration: Speakers' bureau: Janssen, AbbVie, Takeda, Kiowa, Roche, EUSAPharma, Incyte, BeiGene W. Jurczak Consultant or advisory role: MEI Pharma, Debiopharm, Loxo, Takeda, AstraZeneca, BeiGene Research funding: GSK, Acerta, BeiGene, Nordic Nanovector, Debiopharm, Incyte, Genentech, Janssen, Loxo, MEI Pharma, MorphoSys AG, Takeda, TG Therapeutics K. J. Maddocks Honoraria: Pharmacyclics, MorphoSys AG, Bristol-Myers Squibb, Karyopharm Therapeutics, Kite Pharma/Gilead Company, ADC Therapeutics, AbbVie, AstraZeneca, BeiGene, Genmab, Genentech, Janssen, Lilly, Incyte Research funding: Pharmacyclics, Merck, Bristol-Myers Squibb T. Menne Consultant or advisory role: Kite/Gilead, Amgen, Novartis, Pfizer, Celgene/BMS, Daiichi Sankyo, Atara, Roche, Janssen Research funding: Janssen, AstraZeneca, Novartis Educational grants: Amgen, Jazz, Pfizer, Bayer, Kyowa Kirin, Celgene/BMS, Kite/Gilead, Janssen, Takeda Other remuneration: Honoraria for lectures: Kite/Gilead, Takeda, Janssen, Roche, Servier, Novartis, Celgene/BMS, Pfizer Z. Nagy Consultant or advisory role: Takeda, Janssen, AbbVie, Roche, Amgen, Servier, Astellas O. Tournilhac Consultant or advisory role: Takeda, AstraZeneca, BeiGene, Incyte, Janssen, Gilead, AbbVie, Roche, Sandoz, Blueprint A. Bakuli Employment or leadership position: MorphoSys AG Other remuneration: statistical consultancy: Ludwig-Maximilians-University Hospital, Munich, Germany A. Amin Employment or leadership position: MorphoSys AG Stock ownership: Paion AG K. Gurbanov Employment or leadership position: MorphoSys AG G. Salles Consultant or advisory role: Roche/Genentech, Gilead Sciences, Janssen, Celgene, Novartis, MorphoSys AG, Epizyme, Alimera Sciences, Genmab, Debiopharm Group, VelosBio, Bristol-Myers Squibb, BeiGene, Incyte, Miltenyi Biotec, Ipsen Honoraria: Roche/Genentech, Janssen, Celgene, Gilead Sciences, Novartis, AbbVie, MorphoSys AG" @default.
• W4380079400 created "2023-06-10" @default.
• W4380079400 creator A5007117385 @default.
• W4380079400 creator A5011014349 @default.
• W4380079400 creator A5016764336 @default.
• W4380079400 creator A5022412452 @default.
• W4380079400 creator A5024389256 @default.
• W4380079400 creator A5029890875 @default.
• W4380079400 creator A5035549893 @default.
• W4380079400 creator A5041745367 @default.
• W4380079400 creator A5046049357 @default.
• W4380079400 creator A5046659441 @default.
• W4380079400 creator A5052071966 @default.
• W4380079400 creator A5061317839 @default.
• W4380079400 creator A5068281424 @default.
• W4380079400 creator A5074570151 @default.
• W4380079400 date "2023-06-01" @default.
• W4380079400 modified "2023-10-12" @default.
• W4380079400 title "Five‐year subgroup analysis of tafasitamab + lenalidomide from the Phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma" @default.
• W4380079400 doi "https://doi.org/10.1002/hon.3164_324" @default.
• W4380079400 hasPublicationYear "2023" @default.
• W4380079400 type Work @default.
• W4380079400 citedByCount "0" @default.
• W4380079400 crossrefType "journal-article" @default.
• W4380079400 hasAuthorship W4380079400A5007117385 @default.
• W4380079400 hasAuthorship W4380079400A5011014349 @default.
• W4380079400 hasAuthorship W4380079400A5016764336 @default.
• W4380079400 hasAuthorship W4380079400A5022412452 @default.
• W4380079400 hasAuthorship W4380079400A5024389256 @default.
• W4380079400 hasAuthorship W4380079400A5029890875 @default.
• W4380079400 hasAuthorship W4380079400A5035549893 @default.
• W4380079400 hasAuthorship W4380079400A5041745367 @default.
• W4380079400 hasAuthorship W4380079400A5046049357 @default.
• W4380079400 hasAuthorship W4380079400A5046659441 @default.
• W4380079400 hasAuthorship W4380079400A5052071966 @default.
• W4380079400 hasAuthorship W4380079400A5061317839 @default.
• W4380079400 hasAuthorship W4380079400A5068281424 @default.
• W4380079400 hasAuthorship W4380079400A5074570151 @default.
• W4380079400 hasBestOaLocation W43800794001 @default.
• W4380079400 hasConcept C121332964 @default.
• W4380079400 hasConcept C126322002 @default.
• W4380079400 hasConcept C141071460 @default.
• W4380079400 hasConcept C142424586 @default.
• W4380079400 hasConcept C143998085 @default.
• W4380079400 hasConcept C187960798 @default.
• W4380079400 hasConcept C203092338 @default.
• W4380079400 hasConcept C2776063141 @default.
• W4380079400 hasConcept C2776364478 @default.
• W4380079400 hasConcept C2778559949 @default.
• W4380079400 hasConcept C2779338263 @default.
• W4380079400 hasConcept C2780653079 @default.
• W4380079400 hasConcept C2780739268 @default.
• W4380079400 hasConcept C2781413609 @default.
• W4380079400 hasConcept C3019894029 @default.
• W4380079400 hasConcept C31760486 @default.
• W4380079400 hasConcept C44249647 @default.
• W4380079400 hasConcept C535046627 @default.
• W4380079400 hasConcept C71924100 @default.
• W4380079400 hasConcept C87355193 @default.
• W4380079400 hasConcept C90924648 @default.
• W4380079400 hasConceptScore W4380079400C121332964 @default.
• W4380079400 hasConceptScore W4380079400C126322002 @default.
• W4380079400 hasConceptScore W4380079400C141071460 @default.
• W4380079400 hasConceptScore W4380079400C142424586 @default.
• W4380079400 hasConceptScore W4380079400C143998085 @default.
• W4380079400 hasConceptScore W4380079400C187960798 @default.
• W4380079400 hasConceptScore W4380079400C203092338 @default.
• W4380079400 hasConceptScore W4380079400C2776063141 @default.
• W4380079400 hasConceptScore W4380079400C2776364478 @default.
• W4380079400 hasConceptScore W4380079400C2778559949 @default.
• W4380079400 hasConceptScore W4380079400C2779338263 @default.
• W4380079400 hasConceptScore W4380079400C2780653079 @default.
• W4380079400 hasConceptScore W4380079400C2780739268 @default.
• W4380079400 hasConceptScore W4380079400C2781413609 @default.
• W4380079400 hasConceptScore W4380079400C3019894029 @default.
• W4380079400 hasConceptScore W4380079400C31760486 @default.
• W4380079400 hasConceptScore W4380079400C44249647 @default.
• W4380079400 hasConceptScore W4380079400C535046627 @default.
• W4380079400 hasConceptScore W4380079400C71924100 @default.
• W4380079400 hasConceptScore W4380079400C87355193 @default.
• W4380079400 hasConceptScore W4380079400C90924648 @default.
• W4380079400 hasIssue "S2" @default.
• W4380079400 hasLocation W43800794001 @default.
• W4380079400 hasOpenAccess W4380079400 @default.
• W4380079400 hasPrimaryLocation W43800794001 @default.
• W4380079400 hasRelatedWork W1790206647 @default.
• W4380079400 hasRelatedWork W2028031208 @default.
• W4380079400 hasRelatedWork W2036063985 @default.
• W4380079400 hasRelatedWork W2059095707 @default.
• W4380079400 hasRelatedWork W2136651687 @default.
• W4380079400 hasRelatedWork W2589111423 @default.
• W4380079400 hasRelatedWork W3031387218 @default.
• W4380079400 hasRelatedWork W4282047752 @default.
• W4380079400 hasRelatedWork W4295828468 @default.
• W4380079400 hasRelatedWork W2519639378 @default.
• W4380079400 hasVolume "41" @default.
• W4380079400 isParatext "false" @default.
• W4380079400 isRetracted "false" @default.

• next